Blinatumomab 的商品名是Blincyto，俗称blina，是一种生物制药药物，用于治疗费城染色体阴性的复发或难治性急性淋巴细胞白血病的二线治疗。它属于一类合成单克隆抗体，即双特异性 T 细胞接合器(BiTE)，可选择性地发挥作用并指示人体免疫系统对抗肿瘤细胞。

The immunotherapy drug blinatumomab (Blincyto) is already a standard treatment for some people with acute lymphoblastic leukemia (ALL). Following positive results from a large clinical trial, it’s now ...

The National Institute for Health and Care Excellence (NICE) has recommended blinatumomab with chemotherapy for National Health Service (NHS) use in adults with aggressive leukaemia. The ...

Health technology assessment (HTA) agency NICE has just backed the use of Blincyto (blinatumomab) plus chemotherapy for consolidation treatment of Philadelphia chromosome-negative, CD19-positive B ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

This innovative treatment, known as blinatumomab (Blincyto), is set to benefit approximately 80 adults per year and will be available immediately on the NHS. Blinatumomab represents a major ...

and Amgen's bispecific antibody Blincyto (blinatumomab) for CD19-positive ALL. It is also a potential rival to Incyte/MorphoSys' CD19-targeting antibody Minjuvi (tafasitamab) - approved last ...

eDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA fDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ...

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...